What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F
Natura:	Journal article
Lingua:	English
Pubblicazione:	2010

Documenti analoghi

Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
di: Testa, L, et al.
Pubblicazione: (2010)

Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
di: L. Testa, et al.
Pubblicazione: (2010-01-01)

Use of prasugrel in patients with clopidogrel hypersensitivity
di: Aparna Joshi, et al.
Pubblicazione: (2022-01-01)

Interaction between statins and clopidogrel: is there anything clinically relevant?
di: Bhindi, R, et al.
Pubblicazione: (2008)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
di: Satoshi Niijima, et al.
Pubblicazione: (2018-03-01)

Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
di: Testa, L, et al.
Pubblicazione: (2009)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
di: Dongwhane Lee, et al.
Pubblicazione: (2018-09-01)

Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders
di: Philip M Bath, et al.
Pubblicazione: (2018-07-01)

Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
di: Gerhard Selhorst, et al.
Pubblicazione: (2019-04-01)

Repeat thrombolysis or conservative therapy vs. rescue percutaneous coronary intervention for failed thrombolysis: systematic review and meta-analysis.
di: Testa, L, et al.
Pubblicazione: (2008)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
di: Jan Kiebist, et al.
Pubblicazione: (2021-09-01)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
di: Jim McLenachan, et al.
Pubblicazione: (2019-05-01)

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome
di: Muhammad Naufal Hibatullah, et al.
Pubblicazione: (2024-11-01)

Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study
di: Feng-Yu Kuo, et al.
Pubblicazione: (2022-09-01)

Prasugrel
di: Gianluca Airoldi, et al.
Pubblicazione: (2013-04-01)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Pubblicazione: (2019-07-01)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
di: Bartosz Olechowski, et al.
Pubblicazione: (2016-01-01)

Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment
di: Monica Verdoia, et al.
Pubblicazione: (2019-10-01)

Study to assess improvement in therapeutic outcomes by platelet inhibition with prasugrel
di: Amit Madaan
Pubblicazione: (2015-12-01)

Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months
di: Dongwhane Lee, et al.
Pubblicazione: (2019-03-01)

Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
di: Testa, L, et al.
Pubblicazione: (2008)

Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock
di: Vojko Kanic, et al.
Pubblicazione: (2024-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
di: Yuri Kim, et al.
Pubblicazione: (2023-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
di: Yuri Kim, et al.
Pubblicazione: (2023-01-01)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
di: Gabriele Crimi, et al.
Pubblicazione: (2019-01-01)

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
di: Constance C. F. M. J. Baaten, et al.
Pubblicazione: (2015-09-01)

Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery.
di: Testa, L, et al.
Pubblicazione: (2009)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
di: Shokoufeh Hajsadeghi, et al.
Pubblicazione: (2016-01-01)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
di: Shokoufeh Hajsadeghi, et al.
Pubblicazione: (2016-08-01)

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance
di: John I. Louca, et al.
Pubblicazione: (2014-09-01)

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS
di: P. S. LAGUTA, et al.
Pubblicazione: (2017-12-01)

Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?
di: Carlos G. Santos-Gallego
Pubblicazione: (2015-09-01)

The hurdles of translating a single-center observation into practice.
di: Testa, L, et al.
Pubblicazione: (2008)

Digitalis: a dangerous drug in atrial fibrillation?
di: Testa, L, et al.
Pubblicazione: (2008)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
di: Lulu Dai, et al.
Pubblicazione: (2022-06-01)

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry
di: Goldstein P, et al.
Pubblicazione: (2016-04-01)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
di: Zhe Wang, et al.
Pubblicazione: (2020-03-01)

The effect of concurrent clopidogrel and omeprazole administration on clopidogrel metabolism and platelet function in healthy cats
di: Christina Plante, et al.
Pubblicazione: (2024-11-01)

Sepsis favors high-on-clopidogrel platelet reactivity
di: Karolina Akinosoglou, et al.
Pubblicazione: (2018-01-01)

Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders
di: Wiktor Kuliczkowski, et al.
Pubblicazione: (2021-01-01)